FDA Helath Warning

[Guest guest]

Hi all,

I got this in the mail and thought I'd pass it along.

Courage

FDA MedWatch - Permax (pergolide mesylate) associated with fallin g

asleep without warning

>MedWatch - The FDA Safety Information and Adverse Event Reporting Program

>

>FDA and Lilly modified the WARNINGS and PRECAUTIONS sections to inform

>healthcare professionals of the possibility of patients falling asleep

while

>performing daily activities, including operation of motor vehicles, while

>receiving treatment with Permax, a dopamine agonist, indicated as

adjunctive

>treatment to levodopa/carbidopa in the management of the signs and symptoms

>of Parkinson's disease. Many patients who have fallen asleep have perceived

>no warning of somnolence. Healthcare professionals should be alerted to the

>potentially serious risks associated with these events and should carefully

>evaluate their patients for the presence of somnolence.

>

>Read the MedWatch 2003 safety summary, including links to the " Dear

>Healthcare Professional " letter and revised label, at:

>

>http://www.fda.gov/medwatch/SAFETY/2003/safety03.htm#permax2

>

>--------

>

>Thank you for using MedWatch as a trusted source for timely safety

information on drugs and other medical products regulated by the U.S. Food

and Drug Administration. If you find this e-mail notification helpful,

please consider telling colleagues and friends about MedWatch. They can

learn more about us and subscribe/unsubscribe to the e-list at the MedWatch

homepage, http://www.fda.gov/medwatch or by going directly to

http://list.nih.gov/cgi-bin/wa?SUBED1=medwatch & A=1

>

>This is an automated message delivery system -- replying to this message

will not reach MedWatch staff. If you have comments or questions about

MedWatch or this e-mail, please contact us through our comments & feedback

web page, http://www.fda.gov/medwatch/feedback.htm